Renal Stone Inhibitors
The size and the degree of aggregation of crystals, dependent on salt saturation and crystal inhibitor concentration, seem to be the main differences between stone-formers and healthy subjects.
Citrate, pyrophosphate and magnesium inhibit calcium-oxalate and calcium-phosphate crystal formation and growth, while glycosaminoglycans and diphosphonates are crystal aggregation inhibitors.
The role of uric acid in the pathogenesis of calcium-oxalate lithiasis is reviewed, as well as the methods employed for identification and measurement of urinary inhibitors. We present a simple new method to evaluate the inhibitory capacity of urine with regard to calcium-oxalate crystal growth.
KeywordsCalcium Phosphate Stone Formation Calcium Oxalate Amorphous Calcium Phosphate Urinary Calculus
Unable to display preview. Download preview PDF.
- 1.Robertson, W.G. and Nordin, B.E.C.: Physicochemical factors governing stone-formation. In Scientific Fundations in Urology, edited by Williams, D.I. and Chisholm, G.D. pp. 254–267. London, Heinemann (1976).Google Scholar
- 2.Boyce, W.H.: Organic matrix of native human urinary concretions. In Renal Stone Research Symp. edited by Hodgkinson, A. and Nordin, B.E.C. pp. 93–104. London, Churchill, (1969).Google Scholar
- 4.Pak, C.Y.C. and Arnold, L.H.: Heterogeneous nucleation of calcium oxalate by seeds of monosodium urate. Proc. Soc. Exp. Biol. Med. 149: 930,(1975).Google Scholar
- 5.Coe, F.L., Lawton, R.L., Goldstein, R.B. and Temple, V.: Sodium urate accelerates precipitation of calcium oxalate in vitro. Proc. Soc. Exp. Biol. Med. 149: 926, (1975).Google Scholar
- 7.Russell, R.G.G. and Fleisch, H.: Inhibitors in urinary stone disease: Role of pyrophosphate. Urinary Calculi. Int. Symp. Renal Stone Res. Madrid 1972, pp. 307–312 (Karger, Basel 1973).Google Scholar
- 9.Russell, R.G.G. and Hodgkinson, A.: Urinary excretion of inorganic pyrophosphate by normal subjects and patients with renal calculus. Clin. Sci. 31: 51, (1966).Google Scholar
- 10.Thomas, W.C. and Miller, G.M.: Inorganic phosphates in the treatment of renal calculi. Mod. Treatment 4: 494, (1967).Google Scholar
- 11.Smith, L.H., Meyer, J.L. and McCall, J.T.: Chemical nature of crystal inhibitors isolated from human urine. Urinary Calculi. Int. Symp. Renal Stone Res. Madrid 1972, pp. 318–327 (Karger, Basel 1973).Google Scholar
- 12.Fleisch, H. and Russell,R.G.G.: Inhibitors in urinary stone disease: role of diphosphonates. Urinary Calculi. Int. Symp. Renal Stone Res. Madrid 1972, pp. 296–301 (Karger, Basel 1973).Google Scholar
- 13.Lyon, E.S., Borden, T.A., Ellis, J.E. and Vermeulen, C.W.: Calcium oxalate lithiasis produced by pyridoxine deficiency and inhibition with high magnesium diets. Invest. Urol. 4: 133, (1966).Google Scholar
- 14.Robertson, W.G., Knowles, F. and Peacock, M.: Urinary acid mucopolysaccharide inhibitors of calcium oxalate crystallization. In Urolithiasis Research, pp. 331–338, edited by Fleisch, H., Robertson, W.G., Smith, L.H. and Vahlensieck, W Plenum Publishing Corp. New York, 1979.Google Scholar
- 15.Sallis, J.D. and Lumley, M.F.: On the possible role of glysoaminoglycans as natural inhibitors of calcium oxalate stones. Invest. Urol. 16: 296, (1978).Google Scholar
- 16.Foye, W.O., Hong, H.S., Kim, C.M. and Prien, E.L. Sr.: Degree of sulfation in mucopolysaccharide sulfates in normal and stoneforming urines. Invest. Urol. 14: 33, (1976).Google Scholar
- 17.Pak, C.Y.C., Holt, K. and Zerwekh, J.E,: Attenuation by monosodium urate of the inhibitory effect of glycosaminoglycans on calcium oxalate nucleation. Invest. Urol. 17: 138, (1979).Google Scholar